134 related articles for article (PubMed ID: 24878001)
1. Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients.
Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Baranowska A; Siedlecki JA
Leuk Res; 2014 Jul; 38(7):850-6. PubMed ID: 24878001
[TBL] [Abstract][Full Text] [Related]
2. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia.
Ko YC; Fang WH; Lin TC; Hou HA; Chen CY; Tien HF; Lin LI
Leuk Res; 2014 May; 38(5):625-31. PubMed ID: 24703161
[TBL] [Abstract][Full Text] [Related]
4. Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
Annamaneni S; Kagita S; Gorre M; Digumarti RR; Satti V; Battini MR
Hematology; 2014 Jan; 19(1):42-4. PubMed ID: 23541085
[TBL] [Abstract][Full Text] [Related]
5. Aberrant methylation of CCAAT/enhancer binding protein zeta promoter in acute myeloid leukemia.
Yao DM; Qian J; Lin J; Wang YL; Chen Q; Qian Z; Li Y; Wang CZ; Yang J
Leuk Res; 2011 Jul; 35(7):957-60. PubMed ID: 21106240
[TBL] [Abstract][Full Text] [Related]
6. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia.
Lin TC; Hou HA; Chou WC; Ou DL; Yu SL; Tien HF; Lin LI
Leukemia; 2011 Jan; 25(1):32-40. PubMed ID: 20927134
[TBL] [Abstract][Full Text] [Related]
7. Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia.
Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Siedlecki JA
Mol Med Rep; 2015 May; 11(5):3948-54. PubMed ID: 25585874
[TBL] [Abstract][Full Text] [Related]
8. PU.1 and CEBPA expression in acute myeloid leukemia.
D'Alò F; Di Ruscio A; Guidi F; Fabiani E; Greco M; Rumi C; Hohaus S; Voso MT; Leone G
Leuk Res; 2008 Sep; 32(9):1448-53. PubMed ID: 18308386
[TBL] [Abstract][Full Text] [Related]
9. Complexity of miR-223 regulation by CEBPA in human AML.
Eyholzer M; Schmid S; Schardt JA; Haefliger S; Mueller BU; Pabst T
Leuk Res; 2010 May; 34(5):672-6. PubMed ID: 20018373
[TBL] [Abstract][Full Text] [Related]
10. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
[TBL] [Abstract][Full Text] [Related]
11. CEBPA methylation and mutation in myelodysplastic syndrome.
Wen XM; Hu JB; Yang J; Qian W; Yao DM; Deng ZQ; Zhang YY; Zhu XW; Guo H; Lin J; Qian J
Med Oncol; 2015 Jul; 32(7):192. PubMed ID: 26025484
[TBL] [Abstract][Full Text] [Related]
12. Activation of the unfolded protein response in human acute myeloid leukemia.
Schardt JA; Mueller BU; Pabst T
Methods Enzymol; 2011; 489():227-43. PubMed ID: 21266233
[TBL] [Abstract][Full Text] [Related]
13. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
Pabst T; Mueller BU
Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
[TBL] [Abstract][Full Text] [Related]
14. Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.
Cheng CK; Chan NP; Wan TS; Lam LY; Cheung CH; Wong TH; Ip RK; Wong RS; Ng MH
Haematologica; 2016 Apr; 101(4):448-57. PubMed ID: 26802049
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.
Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Farsani MA
Ann Hum Genet; 2017 Nov; 81(6):276-283. PubMed ID: 28895127
[TBL] [Abstract][Full Text] [Related]
16. Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemia.
Jost E; do O N; Wilop S; Herman JG; Osieka R; Galm O
Leuk Res; 2009 Mar; 33(3):443-9. PubMed ID: 18757096
[TBL] [Abstract][Full Text] [Related]
17. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
Mulet-Lazaro R; van Herk S; Erpelinck C; Bindels E; Sanders MA; Vermeulen C; Renkens I; Valk P; Melnick AM; de Ridder J; Rehli M; Gebhard C; Delwel R; Wouters BJ
Blood; 2021 Jul; 138(2):160-177. PubMed ID: 33831168
[TBL] [Abstract][Full Text] [Related]
18. The actin-binding protein CORO1A is a novel PU.1 (SPI1)- and CEBPA-regulated gene with significantly lower expression in APL and CEBPA-mutated AML patients.
Federzoni EA; Humbert M; Valk PJ; Behre G; Leibundgut EO; Torbett BE; Fey MF; Tschan MP
Br J Haematol; 2013 Mar; 160(6):855-9. PubMed ID: 23252456
[No Abstract] [Full Text] [Related]
19. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
20. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
